Navigator Medicines, Inc. raised $100M in a Series A funding round co-led by RA Capital Management and Forbion to advance their bispecific antibody NAV-240 for autoimmune diseases.

Aug 27, 2024•over 1 year ago

Amount Raised

$100 Million

Round Type

series a

Scotch PlainsTherapeuticsBiotechnologyHealth Care

Investors

ForbionRa Capital Management

Description

Navigator Medicines, Inc. has successfully closed a $100 million Series A financing to further develop NAV-240, a bispecific antibody targeting OX40L and TNFα. The funding will accelerate the clinical development of this innovative therapeutic and enhance their broader pipeline of immune regulation biologics.

Company Information

Company

Navigator Medicines

Location

Scotch Plains, New Jersey, United States

About

Navigator Medicines is a biotech company leading the advancement of biologics for targeted immune regulation & restoration. Founded in 2024 as a subsidiary of Sera Medicines, the Company is committed to developing new therapies for patients living with complex, heterogeneous autoimmune diseases. NAV-240, their clinical-stage bispecific antibody, targets OX40L and TNFα to address critical inflammatory diseases. The company is focused on innovation that enhances patient care.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends